These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
    Author: Wang M.
    Journal: Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818.
    Abstract:
    Metabolic syndrome is a group of metabolic abnormalities associated with increased cardiovascular and mortality risks. Glucocorticoid excess has been linked to the development of metabolic syndrome. Intracellular glucocorticoid levels are regulated by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1), a key enzyme that converts inert cortisone to active cortisol. To counter the unfavorable metabolic effects of glucocorticoids in certain tissues, 11beta-HSD-1 inhibitors are being investigated for their potential in the treatment of insulin resistance and other aspects of metabolic syndrome. Several different classes of 11beta-HSD-1 inhibitors are currently under investigation by multiple pharmaceutical companies, highlighting the encouraging progress made in this field.
    [Abstract] [Full Text] [Related] [New Search]